A study of potential treatment-responsive biomarkers and clinical outcomes in Hunter syndrome

To be considered for this study, you or your child would have needed to have a confirmed diagnosis of Hunter Syndrome (MPS II). This diagnosis would have been checked by things like genetic tests, which look for changes in a specific gene called IDS, and laboratory tests measuring the activity of the IDS enzyme in blood or skin cells.

The study was quite broad, including participants from infancy up to 30 years old, and covered both males and females. Depending on which part of the study a person was considered for, there were slightly different age ranges and particular aspects of their condition taken into account. For example, some parts focused on younger children (2 to 10 years old) or adolescents (6 to 17 years old), while other parts looked at specific types of Hunter Syndrome, like those that affect the brain (nMPS II) or those that don't (nnMPS II).

There were also specific requirements about a person's development or thinking abilities, or if they had a close family member with a certain type of Hunter Syndrome. For some parts, participants needed to be having an unrelated medical procedure that involved general anaesthesia or collecting spinal fluid, and they would have agreed to donate some of that fluid for study research. People with unstable medical conditions that would make taking part difficult would not have been able to join.

If you or your child took part in this study, you wouldn't have received any new or experimental medicines for Hunter Syndrome as part of the research. This was an 'observational' study, meaning the researchers were mainly watching and collecting information about how the condition changed naturally over time. You would have continued with your usual medical care for Hunter Syndrome outside of the study.

The study involved several 'parts' or groups of participants, and what was involved might have varied slightly between them. Generally, participation would have included regular assessments of health status, including measuring development and thinking abilities. The study also collected samples like blood, urine, and potentially spinal fluid, to look for those 'biomarkers' we discussed. These would have been collected at regular intervals over the study period. The full study ran from October 2019 to March 2024, so individuals would have taken part for a portion of that time, depending on when they joined and which part of the study they were in.